Advertisement
Product › Details
Debio 1450 (Debiopharm)
Next higher product group | antibiotic | |
Status | 2015-04-23 development p2 start | |
Organisation | Debiopharm International S.A. | |
Group | Debiopharm (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for antibiotic
- [1] Precisio Biotix Therapeutics, Inc.. (3/1/24). "Press Release: Precisio Biotix Therapeutics Acquires London-headquartered CC Bio, Adding World-class Antibacterial Platform and Top Scientists". Dover, DE....
- [2] Omnix Medical Ltd.. (2/20/24). "Press Release: Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6". Jerusalem....
- [3] Antabio S.A.S.. (12/12/23). "Press Release: Antabio Raises €25 Million in Series B Financing". Labège....
- [4] Glox Therapeutics Ltd.. (11/14/23). "Press Release: Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria". Glasgow....
- [5] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
- [6] Newton Biocapital. (6/7/23). "Press Release: Santero Announces a €8 Million Series A Funding Round Led by Newton Biocapital to Develop Novel Antibiotics in the Fight against Antimicrobial Resistance". Brussels....
- [7] Smartbax GmbH. (5/23/23). "Press Release: Smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics". Munich....
- [8] BioVersys AG. (1/5/23). "Press Release: BioVersys Extends Its Series C Round to CHF 32.6 Million with investment from the AMR Action Fund". Basel....
- [9] Aurobac Therapeutics S.A.S.. (10/4/22). "Press Release: Aurobac Therapeutics, the Joint Venture Recently Created by Boehringer Ingelheim, Evotec and bioMérieux, Appoints Florence Séjourné as Chief Executive Officer". Lyon....
- [10] GSK plc. (9/22/22). "Press Release: GSK and Spero Therapeutics Announce Exclusive Licence Agreement for tebipenem HBr, a Late-stage Antibiotic that May Treat Complicated Urinary Tract Infections". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top